1	Appendix	
2		
3		
4	Supplementary Methods	2
5	Supplementary Results	3
6 7	Table S1. Parameters used in assay development software. Parameters used in the development of primers and probes using Primer3Plus (https://primer3plus.com/, accessed 7/16/23).	new 6
8	Table S2. Primers and probes used in this study for different targets.	7
9 10 11	Table S3. Viruses considered in this study and the region of the genome that each virus assay targe Viruses used to test specificity are indicated as "non target testing" and viruses used as positive controls are indicated as "target testing".	ts. 8
12	Table S4. Additional details related to the EMMI guidelines.	9
13	Figure S1. The location of the two sewersheds where samples were collected in this study.	10
14	Figure S2. EMMI15 checklist.	11
15	Figure S3. Multiplex assay performance.	12
16 17	Figure S4. Distribution of Kd values measured in eight samples of paired liquid and solid samples from OSP for each viral target considered herein.	13
18 19	Figure S5. PMMoV-normalized wastewater data and positivity rates.	14

20 **Supplementary Methods**

21

22 (RT-)PCR assays. All primers and probe sequences (including custom and previously published assays, Table S2)

23 were then screened for specificity in silico and in vitro. Assays were tested in vitro for specificity and sensitivity

24 using virus panels (NATtrol[™] Respiratory Verification Panel NATRVP2.1-BIO, NATtrol[™] EV Panel

- 25 NATRVPEVP-C, Zeptometrix, Buffalo, NY), and genomic and synthetic target nucleic acids purchased from
- 26 American Type Culture Collection (ATCC, Manassas, VA) (Table S3). The respiratory virus panel includes
- 27 chemically inactivated intact influenza viruses, parainfluenza viruses, adenovirus, rhinovirus A, metapneumovirus,
- 28 rhinovirus, RSV, several coronaviruses, and SARS-CoV-2; the EV panel includes chemically inactivated intact 29 coxsackieviruses, echovirus, and parechovirus. Nucleic acids were extracted from intact viruses or cells using
- 30 Chemagic Viral DNA/RNA 300 Kit H96 for Chemagic 360 (PerkinElmer, Waltham, MA).
- 31

32 Nucleic acids were used undiluted as template in digital droplet (RT-)PCR singleton assays for sensitivity and

- 33 specificity testing in single wells. The concentration of targets used in the in vitro specificity testing was between
- 34 10³ and 10⁴ copies per well. Negative (RT-)PCR controls were included on each plate.
- 35

36 Solids pre-analytical processing. As mentioned in the main text, these methods have been described in detail

37 previously in published papers^{1,2} and open access protocols^{3,4}. Briefly, a pre-measured mass of dewatered solids was

38 suspended in a buffer at a concentration of 75 mg/ml. The mixture was homogenized and then centrifuged; nucleic-

39 acids were extracted using a commercial kit Chemagic Viral DNA/RNA 300 Kit H96 for Chemagic 360

40 (PerkinElmer, Waltham, MA) and then the nucleic-acids were processed using an inhibitor removal kit (Zymo,

- 41 Irvine, CA). This protocol has been shown to alleviate potential inhibition while maintaining good assay
- 42 sensitivity^{2,5}. 300 μ l of the suspension entered into the nucleic-acid extraction process and 50 μ l of nucleic-acids are
- 43 retrieved after the inhibitor removal kit. An aliquot of the dewater solids was used to determine the dry weight of the 44 solids using oven drying.
- 45

46 Influent pre-analytical processing. For each influent sample, 10 replicate aliquots were processed using an 47 affinity-based capture method with magnetic hydrogel Nanotrap Particles with Enhancement Reagent 1 (Ceres

48 Nanosciences, Manassas, VA) on 10 mL of sample to concentrate viral particles using a KingFisher Flex system 49 following vendor instructions. Nucleic-acids were then extracted from the each concentrated aliquot using the

50 MagMAX Viral/Pathogen Nucleic Acid Isolation Kit (Applied Biosystems, Waltham, MA) on the KingFisher Flex 51 platform to obtain purified nucleic acids which were then process through a Zymo OneStep-96 PCR Inhibitor

52 Removal kit (Zymo Research, Irvine, CA). Each 10 ml sample resulted in 50 µl total nucleic acid extract.

53 54 dd(RT-)PCR methods. The ddRT-PCR methods applied to measure PMMoV in a singleplex reaction are provided 55 in detail elsewhere¹. The human virus assays were run in multiplex using a probe-mixing approach and unique 56 fluorescent molecules (HEX, FAM, Cy5, Cy5.5, ROX, ATTO950) in two sets of reactions. One reaction included 57 primers and probes for rotavirus (fluorescent molecule(s) on probe: FAM), SARS-CoV-2 (FAM/HEX), HuNoV GII 58 (ATTO590), and HAdV (ROX/ATTO590). The second reaction included primers and probes for EV (Cy5.5) and 59 HuNoV GI (ATTO590). Note that the two human virus reactions contained several additional primers and probe sets 60 that yielded results not reported herein. In particular, assays targeting the genomes of West Nile virus, human 61 immunodeficiency virus, hepatitis A virus, Candida auris, and enterovirus D68 and several influenza subtype 62 markers⁶ were included. Each reaction was run on its own 96-well plate.

63

64 Each 96-well PCR plate of wastewater samples included PCR positive controls for each target assayed on the plate

- 65 in 1 well, PCR negative no template controls in two wells, and extraction negative controls (consisting of water and
- 66 lysis buffer) in two wells. PCR positive controls consisted of viral gRNA or gene blocks (Table S3).
- 67

- 68 ddRT-PCR was performed on 20 μl samples from a 22 μl reaction volume, prepared using 5.5 μl template, mixed
- 69 with 5.5 μl of One-Step RT-ddPCR Advanced Kit for Probes (Bio-Rad 1863021), 2.2 μl of 200 U/μl Reverse
- 70 Transcriptase, 1.1 μl of 300 mM dithiothreitol (DTT) and primers and probes mixtures at a final concentration of
- 71 900 nM and 250 nM respectively. Primer and probes for assays were purchased from Integrated DNA Technologies
- 72 (IDT, San Diego, CA) (Table 1). Human virus targets were measured in reactions with undiluted template whereas
- 73 PMMoV was run on template diluted 1:100 in molecular grade water.
- 74
- 75 Droplets were generated using the AutoDG Automated Droplet Generator (Bio-Rad, Hercules, CA). PCR was
- performed using Mastercycler Pro (Eppendforf, Enfield, CT) with with the following cycling conditions: reverse
 transcription at 50°C for 60 minutes, enzyme activation at 95°C for 5 minutes, 40 cycles of denaturation at 95°C for
- transcription at 50°C for 60 minutes, enzyme activation at 95°C for 5 minutes, 40 cycles of denaturation at 95°C for
 30 seconds and annealing and extension at 59°C (for human viruses) or 56°C (for PMMoV) for 30 seconds, enzyme
- 30 seconds and annealing and extension at 59°C (for human viruses) or 56°C (for PMMoV) for 30 seconds, enzyme
 deactivation at 98°C for 10 minutes then an indefinite hold at 4°C. The ramp rate for temperature changes were set
- 80 to 2°C/second and the final hold at 4°C was performed for a minimum of 30 minutes to allow the droplets to
- 81 stabilize. Droplets were analyzed using the QX200 or the QX600 Droplet Reader (Bio-Rad). A well had to have
- 82 over 10,000 droplets for inclusion in the analysis. All liquid transfers were performed using the Agilent Bravo
- 83 (Agilent Technologies, Santa Clara, CA).
- 84
- 85 Thresholding was done using QuantaSoftTM Analysis Pro Software (Bio-Rad, version 1.0.596) and QX Manager
 86 Software (Bio-Rad, version 2.0). Replicate wells were merged for analysis of each sample. In order for a sample to
 87 be recorded as positive, it had to have at least 3 positive droplets.
- 88
- We sought to confirm that the multiplexing up to eight assays did not interfere with target quantification. We tested
 whether the quantification of a single target in the presence of and absence of similar concentrations of the seven
- 91 other targets, including those for which results are not reported in this study, was substantially different. To do so,
- 92 we first quantified three decimal dilutions of a target nucleic acid in the absence of any other targets using the (RT)-
- 93 PCR chemistry that included primers and probes for all eight targets. Then, we quantified the same decimal dilutions
- 94 of the single target in the presence of 10-100 copies per reaction of the seven other targets. Each dilution was run in
- 95 a single well and no template, negative controls were included on each PCR plate. Assays were run and thresholded
- 96 as described above. Results were expressed as copies per reaction and the standard deviation, as output by the
- 97 instrument, were included.
- 98
- Comparison of PMMoV and SARS-CoV-2 measurements on stored versus unstored samples. All the samples used in this study were processed for measurements of SARS-CoV-2 N gene and PMMoV M gene in wastewater solids on unstored samples as a part of a prospective wastewater monitoring program for infectious disease surveillance. The methods for analysis for the N gene through 3/13/23 were identical to those previously described in a Data Descriptor² with the exact same approaches described in this paper except the assay was multiplexed with two other assays using a two color droplet reader (QX200, Bio-rad). Between 3/13/23 and 4/14/23, the N gene was multiplexed with assays for five adjacent single nucleotide polymorphisms (SNPs) in SARS-CoV-2 XBB*,
- respiratory syncytial virus (RSV), influenza A, influenza B, and HuNoV GII in conjunction with a 6-color droplet
 reader (QX600, Bio-rad)⁶⁻⁸.
- 108

109 Supplementary Results

- 110
- 111 **PMMoV measurements in the samples used for the retrospective analysis.** Since PMMoV RNA is present in
- 112 high concentrations in the samples naturally, lack of its detection, or abnormally low measurements might indicate
- gross extraction failures. The median (interquartile range) log₁₀-transformed PMMoV was 9.1 (9.0-9.2) and 8.7 (8.6-

- 8.8) log₁₀ copies/g at SJ and OSP, respectively. The lowest measurements at the two sites were 8.5 (SJ) and 8.1
- (OSP) log₁₀ copies/g and given these lowest values are within an order of magnitude of the medians, we concluded
- that there was no gross extraction failure. We opted to not use an exogenous viral control in these experiments, like
- bovine coronavirus, owing to the complexities associated with interpreting recovery of an exogenous spiked control
- 118 in environmental samples⁹, and its potential to interfere with other uses of the samples, for example viral
- 119 metagenomics.120
- 121 Losses attributable to storage and freeze thaw. We compared measurements of the SARS-CoV-2 N gene and 122 PMMoV M gene made on the samples that were fresh to those used in this study that were stored, and for which the 123 RNA underwent one freeze-thaw. Median (IQR) ratio of PMMoV measurements made in this study to those made 124 using fresh samples was 0.9 (0.6-1.2) at SJ and 1.0 (0.7-1.4) at OSP suggesting limited degradation of the PMMoV 125 target in the stored and freeze-thawed samples. Median ratio of SARS-CoV-2 N gene measurements made in this 126 study to those made using fresh samples was 0.2 (0.1-0.3) at SJ and 0.4 (0.2-0.6) at OSP suggesting storage and 127 freeze thaw may have reduced measurement concentrations, but by less than an order of magnitude.
- 128

Additional details related to the EMMI guidelines. Thirty-six samples from the retrospective study were selected
 at random for this analysis; this represents 8% of the samples processed in the study. As described in the methods

section, each sample was run as template in three different PCR reactions; 1 for PMMoV, 1 for rotavirus, SARS-

132 CoV-2, HuNoV GII, and HAdV, and 1 for EV and HuNoV GI. The average (standard deviation) number of

partitions (droplets) for each of the three reactions (across the 10 replicates) was 164164 (38851) for the reaction for

134 PMMoV, 174321 (20126) for the reaction for rotavirus, SARS-CoV-2, HuNoV GII, and HAdV, and 185497

135 (24410) for the reaction for EV and HuNoV GI. The volume of the partitions, as reported by the machine vendor is

 $136 \quad 0.00085 \ \mu L.$ The mean and standard deviation of copies per partition for each target is shown in Table S4. Example

137 fluorescent plots from the QX200 (two color reader) can be viewed in Topol et al. on protocols.io¹⁰ and an example

- 138 fluorescent plot from the QX600 (6 color reader) is included in the Stanford Digital Repository with the deposited
- 139 data (https://doi.org/10.25740/hr647tm4528).
- 140

141 References

- Wolfe, M. K.; Topol, A.; Knudson, A.; Simpson, A.; White, B.; Duc, V.; Yu, A.; Li, L.; Balliet, M.; Stoddard,
 P.; Han, G.; Wigginton, K. R.; Boehm, A. High-Frequency, High-Throughput Quantification of SARS-CoV-2
 RNA in Wastewater Settled Solids at Eight Publicly Owned Treatment Works in Northern California Shows
 Strong Association with COVID-19 Incidence. *mSystems* 2021, 6 (5), e00829-21.
 https://doi.org/10.1128/mSystems.00829-21.
- 147 (2) Boehm, A. B.; Wolfe, M. K.; Wigginton, K. R.; Bidwell, A.; White, B. J.; Hughes, B.; Duong; Chan-Herur,
 148 V.; Bischel, H. N.; Naughton, C. C. Human Viral Nucleic Acids Concentrations in Wastewater Solids from
 149 Central and Coastal California USA. *Scientific Data* 2023, *10*, 396.
- (3) Topol, A.; Wolfe, M.; White, B.; Wigginton, K.; Boehm, A. High Throughput Pre-Analytical Processing of
 Wastewater Settled Solids for SARS-CoV-2 RNA Analyses. *protocols.io* 2021. https://doi.org/10.17504/protocols.io.btyqnpvw.
- (4) Topol, A.; Wolfe, M.; Wigginton, K.; White, B.; Boehm, A. High Throughput RNA Extraction and PCR
 Inhibitor Removal of Settled Solids for Wastewater Surveillance of SARS-CoV-2 RNA. *protocols.io* 2021.
 https://doi.org/dx.doi.org/10.17504/protocols.io.btyrnpv6.
- Huisman, J. S.; Scire, J.; Caduff, L.; Fernandez-Cassi, X.; Ganesanandamoorthy, P.; Kull, A.; Scheidegger,
 A.; Stachler, E.; Boehm, A. B.; Hughes, B.; Knudson, A.; Topol, A.; Wigginton, K. R.; Wolfe, M. K.; Kohn,
 T.; Ort, C.; Stadler, T.; Julian, T. R. Wastewater-Based Estimation of the Effective Reproductive Number of
 SARS-CoV-2. Environmental Health Perspectives 2022, 130 (5), 057011–1.
- (6) Boehm, A. B.; Wolfe, M. K.; White, B. J.; Hughes, B.; Duong, D.; Bidwell, A. More than a Tripledemic:
 Influenza A Virus, Respiratory Syncytial Virus, SARS-CoV-2, and Human Metapneumovirus in Wastewater
- 162 hindenza A virus, Respiratory Syncyrtar virus, SARS-Cov-2, and Human Metapheumovirus in wast during Winter 2022–2023. *Environ. Sci. Technol. Lett.* **2023**, *10* (8), 622–627.

- 163 https://doi.org/10.1021/acs.estlett.3c00385.
- 164 (7) Boehm, A. B.; Wolfe, M. K.; White, B.; Hughes, B.; Duong, D.; Banaei, N.; Bidwell, A. Human Norovirus (HuNoV) GII RNA in Wastewater Solids at 145 United States Wastewater Treatment Plants: Comparison to Positivity Rates of Clinical Specimens and Modeled Estimates of HuNoV GII Shedders. *Journal of Exposure Science & Environmental Epidemiology* 2023. https://doi.org/10.1038/s41370-023-00592-4.
- 168 (8) Hughes, B.; White, B. J.; Wolfe, M. K.; Boehm, A. B. Quantification of Various SARS-CoV-2 Variant
 169 Mutations (Characteristic of Alpha, Beta, Gamma, Delta, Omicron and Omicron Sublineages) in Settled
 170 Solids Using Digital RT-PCR. Protocols.io 2023. https://dx.doi.org/10.17504/protocols.io.14egnzrrzg5d/v11.
- Kantor, R. S.; Nelson, K. L.; Greenwald, H. D.; Kennedy, L. C. Challenges in Measuring the Recovery of SARS-CoV-2 from Wastewater. *Environ. Sci. Technol.* 2021, 55 (6), 3514–3519.
 https://doi.org/10.1021/acs.est.0c08210.
- 174 (10) Topol, A.; Wolfe, M.; White, B.; Wigginton, K.; Boehm, A. High Throughput SARS-COV-2, PMMOV, and
 175 BCoV Quantification in Settled Solids Using Digital RT-PCR. *protocols.io* 2021.
 176 https://doi.org/10.17504/protocols.io.btywnpxe.
- 177 (11) Loisy, F.; Atmar, R. L.; Guillon, P.; Le Cann, P.; Pommepuy, M.; Le Guyader, F. Real-Time RT-PCR for
- 178 Norovirus Screening in Shellfish. Journal of Virological Methods 2005, 123 (1), 1–7.
- In the second sec
- (13) Jothikumar, N.; Kang, G.; Hill, V. R. Broadly Reactive TaqMan® Assay for Real-Time RT-PCR Detection of Rotavirus in Clinical and Environmental Samples. *Journal of Virological Methods* 2009, *155* (2), 126–131. https://doi.org/10.1016/j.jviromet.2008.09.025.
- (14) Gregory, J. B.; Litaker, R. W.; Noble, R. T. Rapid One-Step Quantitative Reverse Transcriptase PCR Assay
 with Competitive Internal Positive Control for Detection of Enteroviruses in Environmental Samples. *Applied* and Environmental Microbiology 2006, 72 (6), 3960–3967.
- (15) Borchardt, M. A.; Boehm, A. B.; Salit, M.; Spencer, S. K.; Wigginton, K. R.; Noble, R. T. The Environmental Microbiology Minimum Information (EMMI) Guidelines: QPCR and DPCR Quality and Reporting for Environmental Microbiology. *Environ. Sci. Technol.* 2021, 55 (15), 10210–10223. https://doi.org/10.1021/acs.est.1c01767.
- 193

195 Table S1. Parameters used in assay development software. Parameters used in the development of new 196 primers and probes using Primer3Plus (https://primer3plus.com/, accessed 7/16/23).

- 197 198 199 200 201 202 203 203 204 205 Product size ranges: 60-275 • •
 - Primer size: min 15 bp, opt 20 bp, max 36 bp Primer melting temperature: min 50°C, optimal 60°C, max 65°C •
 - GC% content: min 40%, optimal 50%, high 60% ٠
- concentration of divalent cations = 3.8 mM
- concentration of dNTPs needs to be 0.8 mM
 - Internal Oligo: size min 15 bp, optimal 20 bp, max 30 bp
 - Internal Oligo: Melting temp min 62°C, optimal 63°C, max 70°C ٠
- Internal Oligo: GC% min 30%, optimal 50%, max 80%

Target	Primer/Probe	Sequence			
HAdV (183bp)	Forward	CCTCCTGTGTTACGCCAGA			
	Reverse	CAGGCTGAAGTASGTATCGG			
	Probe	CTCGATGATGCCGCAATGGT			
HuNoV GII (88bp)	Forward	ATGTTCAGRTGGATGAGRTTCTCWGA			
	Reverse	TCGACGCCATCTTCATTCACA			
	Probe	AGCACGTGGGAGGGCGATCG			
HuNoV GI (76bp)	Forward	GCCATGTTCCGITGG ATG			
	Reverse	TCCTTAGACGCCATCATCAT			
	Probe	TG GGACAGGAGATCGCAATCTC			
Rotavirus (113bp)	Forward	CAGTGGTTGATGCTCAAGATGGA			
	Reverse	TCATTGTAATCATATTGAATACCCA			
	Probe	ACAACTGCAGCTTCAAAAGAAGWGT			
EV (143bp)	Forward	CCCTGAATGCGGCTAAT			
	Reverse	TGTCACCATAAGCAGCCA			
	Probe	ACGGACACCCAAAGTAGTCGGTTC			
SARS-CoV-2 (143bp)	Forward	CATTACGTTTGGTGGACCCT			
	Reverse	CCTTGCCATGTTGAGTGAGA			
	Probe	CGCGATCAAAACAACGTCGG			
PMMoV	MMoV GAGTGGTTTGACCTTAACGTTTGA Forward				

(68bp)	Reverse	TTGTCGGTTGCAATGCAAGT
	Probe	CCTACCGAAGCAAATG

- 209 Table S2. Primers and probes used in this study for different targets. The size of the amplicon generated by
- 210 the primers is shown under the target name (units of basepairs, bp). Primers and probes were purchased
- 211 from Integrated DNA Technologies (Coralville, IA, USA). All probes contained fluorescent molecules and
- 212 quenchers (5' HEX, FAM, Cy5, Cy5.5, ROX, and/or ATTO950/ZEN/3' IBFQ); FAM, 6-fluorescein amidite;
- 213 HEX, hexachloro-fluorescein; Cy5, Cyanine-5; Cy5.5, Cyanine5.5; ROX, carboxyrhodamine; ZEN, a
- 214 proprietary internal quencher from Integrated DNA Technologies (Coralville, IA, USA); and IBFQ, Iowa
- 215 Black FQ. HAdV is human adenovirus group F, HuNoV is human norovirus, and EV is enterovirus.

Virus	Genomic target	Non-target testing (negatives)	Target testing (positives)	Reference
Adenovirus F (HAdV)	Hexon gene	NATRVP2.1-BIO	ATCC VR-930DQ	Not applicable
Norovirus GII (HuNoV GII)	ORF1-2 junction	NATRVP2.1-BIO	ATCC VR-3235SD	Loisy et al. ¹¹
Norovirus G1 (HuNoV GI)	ORF1-2 junction	NATRVP2.1-BIO NATEVP-C	ATCC VR-3234SD	Jothikuman et al. ¹²
Rotavirus	Non-structural Region Protein 3 (NSP3)	NATRVP2.1-BIO NATEVP-C	ATCC VR-2018DQ	Jothikumar et al. ¹³
Enterovirus (EV)	5' UTR	NATRVP2.1-BIO	NATEVP-C	Gregory et al. ¹⁴

218 Table S3. Viruses considered in this study and the region of the genome that each virus assay targets. Viruses

used to test specificity are indicated as "non target testing" and viruses used as positive controls are indicated

as "target testing". The reference for each assay is provided aside from HAdV for which an assay was

developed herein. All non-target controls are panels sold by Zeptomatrix (panels begin with NAT prefix,

222 "Zepto", Buffalo, NY). ATCC is American Type Culture Collection. The NATRVP2.1-BIO panel includes

223 chemically inactivated intact influenza viruses, parainfluenza viruses, adenovirus, rhinovirus,

224 metapneumovirus, and coronaviruses. The NATEVP-C panel includes chemically inactivated intact

coxsackieviruses, echovirus, and parechovirus. The full list of species in the panels is available from the
 vendor.

227

Table S4. Additional details related to the EMMI guidelines. For each target measured in this study, the

mean and standard deviation (sd) of the total number of copies of target per partition. Num is the number of samples out of a random 36 included in this analysis that had detectable target in them and thus contributed

to the calculated mean and standard deviation. A value of 0 indicates that of the random 36 samples selected,

and the target present in them. Abbreviations for the targets are provided in the main text

except "Rota" is rotavirus and SC2 is the N gene of SARS-CoV-2.

Target	EV	HuNoV GI	Rota	SC2	HuNoV GII	HAdV	PMMoV
mean	1.02x10 ⁻³	8.93x10 ⁻⁴	1.20x10 ⁻⁴	1.37x10 ⁻³	1.12x10 ⁻²	5.03x10 ⁻²	0.15
sd	3.65x10 ⁻⁴	7.94x10 ⁻⁴	1.14x10 ⁻⁴	1.22x10 ⁻³	8.57x10 ⁻³	3.58x10 ⁻²	0.069
num	36	36	23	36	36	36	36

235






Figure S2. EMMI¹⁵ checklist. The checklist is also available at the Stanford Digital Repository with the deposited data (https://doi.org/10.25740/hr647tm4528).

Study							
Description	Environmental Sampling	Sample Treatment	Sample Reduction	Nucleic-acid Extraction	Reverse Transcription	PCR Amplification	Analysis
Study name: enteric virus Date: 8/17/23 Completed by: Boehm	Notes: Described in detail in the methods section	Notes: No sample treatment done	Notes: Described in detail in the methods section	Notes: Described in detail in the methods section	Notes: Described in detail in the methods section	Notes: Described in detail in the methods section	Notes: Described in detail in the methods section
Control Checklist Step performed	Environmental Sampling	Sample Treatment	Sample Reduction	Nucleic-acid Extraction	Reverse Transcription	PCR Amplification	I
atep penormed	2						
Step has control info # of control replicates Control result reported		na D	。 。	2 2	2	2 7	Negative
Method for handling failed controls described							controls
Step has control info Control identity described Control quantification method described # control replicates Control result reported Method for handling failed controls described			2 2 10 2	- - - -	• • •		Positive controls
Process checklist							
Environmental Sampling		Nucleic-acid Extraction		qPCR or dPCR		Analysis-dPCR	
Sample procedure		Extraction procedure	J	Target gene name, amplicon length		Threshold settings	
Number of samples	~	Volume or mass extracted, volume or mass obtained		Thermocycling temp and times	~	Technical replicates, number, well merging	U
Sample amount, mean, range		Extract storage conditions		Master mix composition: vendors, concentrations		Partitions measured, number, mean, variance	
Sampling locations, dates, times		Reverse Transcription		Additives: vendors, composition		Partition volume	V
Sample storage conditions	2	One- or two-step		Template amount added, pre-treatment (if any)	2	Target copies per partition, mean, variance	
Sample Treatment		cDNA storage conditions (if 2 step)		Primers: sequences, concentrations, vendors, references		Program used for dPCR analysis	
Treatment procedure		Reaction temperatures and times		Amplicon confirmation method (probe, met curve details, etc)		Explanation of control results, example plots	J
Reagents		Reaction reagents and concentrations		Probe sequence, concentration, vendor, reference		Analysis- qPCR	
Sample Reduction		Priming method		Instrumentation		Technical replicates, number, calculations	
Reduction procedure		Reaction volume, added template amount		Inhibition assessment procedure		Calibration standards, description, source	
Reagents	~	RT efficiency assessment procedure (if 2-step)		Inhibition control description (if used)		Method of quantifying standards	
Concentration factor	2	RT control description (if two-step)		Number of samples tested and found inhibited	2	Calibration curve slope	
		RT efficiency reported (if 2-step)				Calibration curve R2	
						Lowest standard measured or 95% LOD	
Note to users: This che prescriptive. Not all item Version 2.0						Cq value determination methods	
This version maintained to Date: 4 August 2023	by Borchardt, Boehm, Sa	lit, Noble, Wiggington, S	pencer				






Figure S3. Multiplex assay performance. The concentrations of the different targets in units of copies
per reaction input and measured in each experiment is provided. The white symbols are for reactions
without the 7 background nucleic-acid targets and black symbols include high concentrations of the 7
other nucleic-acid targets. Error bars are standard deviations, if error bars cannot be seen, then they
are smaller than the symbol. The line represents the 1:1 line. "Meas" is measured, "Rota" is rotavirus.
Abbreviations for the different targets are provided in the main text.






Figure S4. Distribution of Kd values measured in eight samples of paired liquid and solid samples from OSP for each viral target considered herein. The points represent each of the eight K_d values. The midline of each box is the median and the edges of the box represent the 25th and 75th percentiles. The whiskers extend to the 9th and 91st percentiles. Rota is rotavirus, and the remaining abbreviations are used in the text of the paper. The order of the viruses from top to bottom of the y-axis is smallest to largest median K_d.




Figure S5. PMMoV-normalized wastewater data. Positivity rates from the clinical laboratory for

rotavirus, adenovirus group F, and norovirus infections (top panels), and concentrations of EV,

rotavirus, HAdV, and HuNoV G1 and GII nucleic-acids in wastewater solids at OSP (middle panels) and

SJ (bottom panels) normalized by concentrations of PMMoV measured in the sample. The solid lines in the wastewater plots represent smoothing using the median of 3-adjacent samples. The norovirus plots

- show GII in green (right axes) and GI in black (left axis).